Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T‐cell lymphoma with analysis of biomarkers
Authors:
Open Access
- 15 April 2011
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 153 (5) , 582-588
Abstract
Summary: Peripheral T‐cell lymphoma (PTCL) has a poorer prognosis than diffuse large B‐cell lymphoma (DLBCL). We administered the CyclOBEAP regimen (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) to patients with DLBCL, and reported its safety and efficacy. Here, we report the results of a multicentre phase II study of the CyclOBEAP regimen in patients with PTCL. In addition, NME1 remained a prognostic factor for survival, as shown in patients who were treated with CyclOBEAP. There were 84 eligible patients and the median age was 54 years. The 5‐year overall survival (OS) rate was 72% and progression‐free survival (PFS) rate was 61%. The 5‐year OS was 93% among the anaplastic large‐cell lymphoma cases, 74% among the angioimmunoblastic T‐cell lymphoma cases, and 63% among the cases of PTCL‐not otherwise specified. When the patients were divided according to the International Prognostic Index or Prognostic Index for PTCL, the 5‐year OS and PFS rates did not significantly differ among the risk groups. Positivity for NME1 was found to be a significant independent prognostic factor. Grade 4 neutropenia was observed in 80 patients and thrombocytopenia in nine patients. Our results suggest that the CyclOBEAP therapy is safe and effective for PTCLs. Furthermore, the NME1 protein may be an important prognostic factor in PTCL.Keywords
This publication has 26 references indexed in Scilit:
- Upfront VIP‐reinforced‐ABVD (VIP‐rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS‐LTP95British Journal of Haematology, 2010
- Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B‐cell lymphomaHematological Oncology, 2010
- A clinicopathological study of nm23-H1 expression in classical Hodgkin’s lymphomaAnnals of Oncology, 2008
- Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trialsBlood, 2008
- Clinico‐pathologic features and outcome of Japanese patients with peripheral T‐cell lymphomasHematological Oncology, 2008
- Prognosis and Primary Therapy in Peripheral T-Cell LymphomasHematology-American Society Hematology Education Program, 2008
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHLBlood, 2004
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958